神经肽Y参与痛觉调制的研究进展

神经肽Y（NPY）是中枢神经系统内含量最多的神经肽之一,它参与机体多种生理活动。近年来,对不同痛模型中NPY作用的研究表明,NPY可能通过激活脊髓和脊髓上水平的Y1受体或拮抗背根节的Y2受体发挥镇痛作用,此类研究将为NPY及其受体激动剂在镇痛中的应用提供重要的理论基础。本文就NPY及其Y1、Y2受体在痛觉调制中的作用作一简要综述。     

神经肽Y及其受体Y1、Y2对痛觉调制的研究进展

神经肽Y（neuropeptide Y,NPY）是一种由36个氨基酸残基组成的肽类激素,属胰多肽家族,广泛分布于中枢及外周神经组织的神经元中。NPY主要参与摄食行为、心血管活动、垂体分泌等生理功能的调节。NPY还参与了痛觉调制。NPY受体有Y1、Y2、Y3、Y4、Y5和Y6六种亚型。目前对Y1受体和Y2受体的研究较多,显示Y1受体和Y2受体参与痛觉调制。但现在对NPY在痛觉中的具体作用机制还不清楚。该文对NPY及其Y1受体、Y2受体在痛觉调制中的作用作一概述。     

大鼠脊髓背角神经元中酸敏感离子通道的特性和功能研究

酸敏感离子通道（ASICs）是一类能被细胞外酸所激活的配体门控离子通道。本文综合报道大鼠脊髓背角神经元中ASICs的亚基组成及其功能性调节：（1）脊髓背角主要表达ASIC1a、ASIC2a和ASIC2b,但不表达ASIC1b和ASIC3;（2）在脊髓背角神经元中酸诱导电流可能由ASIC1a同聚体通道所介导;（3）胞外痛觉信号如实验性缺血和神经肽FMRF可以通过不同的机制增强脊髓背角神经元酸诱导电流;（4）炎症痛可以上调脊髓背角ASICs在转录和蛋白水平的表达。上述各点提示,在生理或病理情况下脊髓背角ASICs对脊髓水平的感觉信息传递特别是痛觉的传导可能发挥着重要作用。     

大鼠NPY Y2受体基因的克隆及C端肽的表达和纯化

Y2受体亚型是早期发现的NPY的两种主要受体亚型之一,参与NPY所介导的多种生理和病理功能.为了制备Y2受体抗体和开展Y2受体的定位研究,用RT-PCR方法从大鼠海马的总RNA扩增NPY的Y2受体全长基因,接着PCR扩增Y2受体的C端片段,克隆入表达载体中,建立了重组NPY Y2受体C端肽的表达菌株,并对表达产物进行纯化.     

神经肽拮抗剂

由于肽的分离纯化、结构分析、化学合成、放射免疫、组织化学定位以及重组DNA等技术的应用,已发现的神经肽的数目与日俱增;但其中多数神经肽的生理功能尚不清楚,原因之一是缺乏特异性的拮抗剂。在神经系统中,神经肽可能起神经递质或神经调节物的作用;在神经内分泌、旁分泌及内分泌系统,又可能起激素的作用。神经肽拮抗剂能在受体水平阻断神经肽的作用,因而可用来推测神经肽在生理及病理状态下的功能;它们又可用于神经肽受体性质的研究以及受体亚型的分型。它们可能发展成为新型的诊断药或治疗药。     

P2Y1嘌呤受体在心血管系统的研究进展

P2Y1嘌呤受体是最早被发现并克隆的P2Y受体家族成员,属G蛋白偶联受体,其内源性激动剂主要是ADP及ATP。随着研究深入,人们发现该受体在多个方面有着重要作用,参与机体多种生理病理过程。本文对该受体近年来在心血管系统方面的研究进行综述,提示P2Y1受体有可能成为疾病治疗的潜在靶点。     

中脑导水管周围灰质内微量注射神经肽γ减弱慢性神经痛大鼠对伤害性刺激的反应

探讨神经肽Y(neuropeptide Y,NPY)在SD大鼠中脑导水管周围灰质(periaqueductal grey,PAG)对伤害性刺激反应的作用。应用热板和机械压力实验法,以大鼠后爪缩爪反应潜伏期(paw withdrawal latency,PWL)为痛阈指标。观察PAG内微量注射NPY对PWLS的影响。PAG内注射0．05、0．1、0．2nmol NPY均显著地增加慢性神经痛大鼠的双侧PWLS,且呈量效关系。NPY引起的PWLs增加可被Y1受体拮抗剂和阿片受体拮抗剂所阻断。结果提示,在大鼠PAG微量注射NPY可产生明显的镇痛作用。     

P2X7受体敲除对小鼠骨癌痛的影响北大核心CSCD

癌痛是临床晚期恶性肿瘤患者常见的临床表现之一。其中,以肺癌、乳腺癌和前列腺癌等骨转移引起疼痛尤为严重。P2X7受体是ATP门控离子通道型嘌呤能受体的一个亚型,在脊髓背角主要表达在胶质细胞。P2X7受体激活可以促进胶质细胞释放多种炎症介质,介导脊髓中枢敏化。该受体在炎症痛及神经病理性疼痛中的作用已多有报道,但在癌痛中的作用尚有争议。本研究采用C57BL/6J小鼠股骨骨髓腔内接种Lewis肺癌细胞所诱导的骨癌痛小鼠模型,分析对比了野生型小鼠和P2X7受体基因敲除(P2rx7-/-)小鼠骨癌痛的发生、发展。野生型C57BL/6J小鼠股骨骨髓腔内接种Lewis肺癌细胞后,患侧后肢分别在第7和14天开始出现明显的触诱发痛和热痛过敏,并呈进行性加重;Cat Walk步态分析显示骨癌第21和28天,小鼠患侧脚印面积明显减小,站立时相持续时间缩短,举步时相持续时间显著延长;组织病理学结果显示受累骨骨髓腔有大量肿瘤细胞浸润,骨髓质正常结构消失,伴有髓质骨和皮质骨的破坏。与研究设计时的预期相反,P2rx7-/-小鼠接种瘤细胞后,患肢痛行为检测结果与野生型小鼠相似,甚至在Cat Walk步态分析检测值变化发生的时间上较野生小鼠有所提前。这与本研究组前期在大鼠骨癌痛模型观察到的阻断P2X7受体明显对抗骨癌痛的结果完全不同,提示P2X7受体在大、小鼠骨癌痛中可能发挥不同的作用,并再次提示疾病动物模型上的研究结果与人类疾病机理之间还存在巨大差异。     

VGF 及其衍生肽

神经肽VGF广泛存在于中枢神经系统和外周神经系统中,在垂体、肾上腺髓质、胃肠内分泌细胞和胰岛β细胞中亦有表达。神经细胞/内分泌细胞表达VGF多肽受到神经营养因子、神经元活性等因素的调控。目前证实,VGF及其衍生肽参与生物体的能量平衡、新陈代谢以及生殖发育等的凋节。在神经系统变性病及情感性精神障碍的相关研究也日益受到关注。本文就神经肽VGF及其衍生肽的生化、生理特性及病理生理作用做一综述。     

VGF及其衍生肽

神经肽VGF广泛存在于中枢神经系统和外周神经系统中,在垂体、肾上腺髓质、胃肠内分泌细胞和胰岛B细胞中亦有表达。神经细胞／内分泌细胞表达VGF多肽受到神经营养因子、神经元活性等因素的调控。目前证实,VGF及其衍生肽参与生物体的能量平衡、新陈代谢以及生殖发育等的凋节。在神经系统变性病及情感性精神障碍的相关研究也日益受到关注。本文就神经肽VGF及其衍生肽的生化、生理特性及病理生理作用做一综述。     

Neuropeptide Y is neuroproliferative for post-natal hippocampal precursor cells

New neurones are produced in the adult hippocampus throughout life and are necessary for certain types of hippocampal learning. Little, however, is known about the control of hippocampal neurogenesis. We used primary hippocampal cultures from early post-natal rats and neuropeptide Y Y1 receptor knockout mice as well as selective neuropeptide Y receptor antagonists and agonists to demonstrate that neuropeptide Y is proliferative for nestin-positive, sphere-forming hippocampal precursor cells and beta-tubulin-positive neuroblasts and that the neuroproliferative effect of neuropeptide Y is mediated via its Y1 receptor. Immunohistochemistry confirmed Y1 receptor staining on both nestin-positive cells and beta-tubulin-positive cells in culture and short pulse 5-bromo-2-deoxyuridine studies demonstrated that neuropeptide Y has a proliferative effect on both cell types. These studies suggest that the proliferation of hippocampal neuroblasts and precursor cells is increased by neuropeptide Y and, therefore, that hippocampal learning and memory may be modulated by neuropeptide Y-releasing interneurones.     

Evidence of a specific pancreatic polypeptide receptor in rat arterial smooth muscle.

Pancreatic polypeptide (PP) is a member of the PP fold family of regulatory peptides. Studies have shown that neuropeptide Y, peptide YY, and PP increased gastrointestinal motility. The GI effects of neuropeptide Y and peptide YY were accompanied by an increase in mean arterial blood pressure; however, PP decreased mean arterial blood pressure. Cloning of a receptor of the neuropeptide Y family with high affinity for PP has been reported. This Y4 receptor is present in intestine, pancreas, and prostate, and its mRNA has been detected in brain and coronary artery. We found in vitro evidence of PP-mediated inhibition of arterial neurogenic vasoconstriction. We have also detected Y4 mRNA in rat peripheral arteries. These findings suggest a potential role for the Y4 receptor in regulating vascular tone.     

Cloned neuropeptide Y (NPY) Y1 and pancreatic polypeptide Y4 receptors expressed in Chinese hamster ovary cells show considerable agonist-driven internalization, in contrast to the NPY Y2 receptor.

Guinea-pig neuropeptide Y1 and rat pancreatic polypeptide Y4 receptors expressed in Chinese hamster ovary cells were internalized rapidly upon attachment of selective peptide agonists. The Y1 and Y2, but not the Y4, receptor also internalized the nonselective neuropeptide Y receptor agonist, human/rat neuropeptide Y. The internalization of guinea-pig neuropeptide Y2 receptor expressed in Chinese hamster ovary cells was small at 37 degrees C, and essentially absent at or below 15 degrees C, possibly in connection to the large molecular size of the receptor-ligand complexes (up to 400 kDa for the internalized fraction). The rate of intake was strongly temperature dependent, with essentially no internalization at 6 degrees C for any receptor. Internalized receptors were largely associated with light, endosome-like particulates. Sucrose dose-dependently decreased the internalization rate for all receptors, while affecting ligand attachment to cell membrane sites much less. Internalization of the Y1 and the Y4 receptors could be blocked, and that of the Y2 receptor significantly inhibited, by phenylarsine oxide, which also unmasked spare cell-surface receptors especially abundant for the Y2 subtype. The restoration of Y1 and Y4 receptors after agonist peptide pretreatment was decreased significantly by cycloheximide and monensin. Thus, in Chinese hamster ovary cells the Y1 and Y4 receptors have much larger subcellular dynamics than the Y2 receptor. This differential could also hold in organismic systems, and is comparable with the known differences in internalization of angiotensin, bradykinin, somatostatin and opioid receptor subtypes.     

Synthesis and evaluation of substituted 4-alkoxy-2-aminopyridines as novel neuropeptide Y1 receptor antagonists

A series of substituted 4-alkoxy-2-aminopyridines 2, which were formally derived from neuropeptide Y1 antagonist 1 by replacing the morpholino portion with alkoxy groups, were synthesized and evaluated as neuropeptide Y Y1 receptor antagonists. Primary structure-activity relationships and identification of potent 4-alkoxy derivatives are described.     

Functional characterization of human neuropeptide Y receptor subtype five specific antagonists using a luciferase reporter gene assay

Neuropeptide Y (NPY) has several receptors; one of them, the neuropeptide Y5 receptor (NPY5) seems involved in feeding behavior in mammals. Although this particular receptor has been extensively studied in the literature, the difficulties encountered to obtain a stable cell line expressing this recombinant receptor have impaired the development of tools necessary to establish its molecular pharmacology. We thus established a method for the functional study of new ligands. It is based upon the cotransfection in human melatonin receptor 1 (MT1)-overexpressing HEK293 cells of three plasmids encoding melanocortin receptor (MC5), neuropeptide Y5 receptor (NPY5) and a cyclic AMP response element-controlled luciferase. Once challenged with alphaMSH, the MC5 receptor activates the cyclic AMP response, through the coupling protein subunit G(s). In contrast, NPY5 agonists, through the NPY5 receptor which is negatively coupled to the same pathway, counteract the alphaMSH-mediated effect on cyclic AMP level. Using appropriate controls, this method can pinpoint compounds with antagonistic activity. Simple and straightforward, this system permits reproducible measurements of agonist or antagonist effects in the presence of neuropeptide Y, the natural agonist. This method has the advantage over already existing methods and beyond its apparent complexity, to enhance the cyclic AMP concentration at a 'physiological' level, by opposition to a forskolin-induced adenylate cyclase activation. Finally, to further validate this assay, we showed results from (1) a series of natural peptidic agonists that permitted the standardization and (2) a series of potent nonpeptidic antagonists (affinity >10(-9) M) that form a new class of active NPY5 receptor antagonists.     

Distinct Changes in Peptide YY Binding to, and mRNA Levels of, Y1 and Y2 Receptors in the Rat Hippocampus Associated with Kindling Epileptogenesis

Abstract: Electrical kindling of the rat dorsal hippocampus induced significant changes in the binding of ¹²⁵I-peptide YY to Y1 and Y2 subtypes of neuropeptide Y receptors and in their mRNA levels in the area dentata as assessed by quantitative receptor autoradiography and in situ hybridization histochemistry. Binding to Y1 receptor sites decreased by 50% ( p < 0.05) in the molecular layer of the stimulated dentate gyrus, 2 days after preconvulsive stage 2 and 1 week or 1 month after generalized stage 5 seizures compared with sham-stimulated rats. Binding to Y2 receptor sites increased bilaterally by 36–87% ( p < 0.05) in the hilus at stage 2 and 1 week or 1 month after stage 5. No significant changes were observed after one afterdischarge or in the other hippocampal subfields or in the cortex. Y1 receptor mRNA signal decreased bilaterally by 50–64% ( p < 0.01) in the granule cell layer, 6 h but not 24 h after stages 2 and 5. The Y2 receptor mRNA signal was enhanced by 283% ( p < 0.01) in the stimulated granule cell layer 24 h after stage 2. At 6 and 24 h after stage 5, mRNA levels were increased both ipsilaterally (283 and 360%, respectively; p < 0.01) and contralaterally (190 and 260%, respectively; p < 0.05). No significant changes in level of either mRNA was found following one afterdischarge. These modifications, and the enhanced neuropeptide Y release previously shown in the hippocampus, suggest that kindling is associated with lasting changes in neuropeptide Y-mediated neurotransmission.     

Presynaptic and Postsynaptic Effects of Neuropeptide Y in the Rat Pineal Gland

Abstract: Neuropeptide Y is colocalized with noradrena-line in sympathetic fibers innervating the rat pineal gland. In this article we present a study of the effects and mechanisms of action of neuropeptide Y on the pineal noradrenergic transmission, the main input leading to the rhythmic secretion of melatonin. At the presynaptic level, neuropeptide Y inhibits by 45%, with an EC₅₀ of 50 n M , the potassium-evoked noradrenaline release from pineal nerve endings. This neuropeptide Y inhibition occurs via the activation of pertussis toxin-sensitive G protein-coupled neuropeptide Y-Y2 receptors and is independent from, but additive to, the α₂-adrenergic inhibition of noradrenaline release. At the postsynaptic level, neuropeptide Y decreases by a maximum of 35%, with an EC₅₀ of 5 n M , the β-adrenergic induction of cyclic AMP elevation via the activation of neuropeptide Y-Y1 receptors. This moderate neuropeptide Y-induced inhibition of cyclic AMP accumulation, however, has no effect on the melatonin secretion induced by a β-adrenergic stimulation. On the contrary, in the presence of 1 m M ascorbic acid, neuropeptide Y potentiates (up to threefold) the melatonin secretion. In conclusion, this study has demonstrated that neuropeptide Y modulates the noradrenergic transmission in the rat pineal gland at both presynaptic and postsynaptic levels, using different receptor subtypes and transduction pathways.     

Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms

Central administration of neuropeptide Y (NPY) stimulates hyperphagia and hyperinsulinemia. Recent evidence has suggested that the Y1 and Y5 receptor subtypes may both mediate NPY-stimulated feeding. The present study attempts to further characterize the role of central NPY receptor subtypes involved in hyperinsulinemia. NPY and peptide analogs of NPY that selectively activated the NPY Y1 or Y5 receptor subtype induced feeding and hyperinsulinemia in satiated Long Evans rats, whereas NPY analogs that selectively activated the NPY Y2 or Y4 receptor subtype did not. To determine whether NPY-induced hyperinsulinemia is secondary to its hyperphagic effect, we compared the plasma insulin levels in the presence and absence of food after a 1-min central infusion of NPY and its analogs at 15, 60, and 120 min postinfusion. Our data suggest that selective activation of central NPY Y1 receptor subtype induced hyperinsulinemia independent of food ingestion, whereas the NPY Y5 receptor-induced hyperinsulinemia was dependent on food ingestion. Central administration of the selective Y1 receptor agonist D-Arg25 NPY eventually decreased plasma glucose levels 2 h postinfusion in Long Evans rats.     

Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage functions in vitro: counter regulation through Y1 and Y2/5 receptors

It is well documented that neuropeptide Y (NPY) exerts a wide range of biological functions through at least five NPY Y receptor subtypes (Y1-Y5), but its immunological effects only recently came into focus. Using NPY family peptides and NPY-related receptor-specific peptides as well as Y1 and Y2 receptor antagonists, we have tested which NPY Y receptors are involved in NPY-induced modulation of rat peritoneal macrophage function in vitro. NPY and PYY increased oxidative burst in phorbol myristate acetate (PMA)-stimulated macrophages involving activation of protein kinase C (PKC), and decreased it in zymosan-stimulated cells resembling inhibition of signaling pathways subsequent to binding of zymosan particles for the iC3b fragment receptor on macrophages. The combined treatment with NPY and NPY Y receptor antagonists revealed that NPY-induced potentiation of oxidative burst in PMA-stimulated cells is mediated through Y1 and Y2 receptors, while NPY-induced suppression in zymosan-stimulated cells is mediated through Y2 receptors only. NPY-related peptides differently modulated macrophage function, confirming involvement of NPY Y2 receptor in both potentiation and suppression of oxidative burst in these cells. Additionally, it was shown that NPY Y5 receptor mediated suppression of oxidative burst in PMA- and zymosan-stimulated macrophages. Taken together, the present data reveal an NPY Y1 and Y2/Y5 receptor interaction in NPY-induced modulation of macrophage functions related to inflammation.     

Emerging functions of neuropeptide Y Y(2) receptors in the brain

The Y(2) receptor is the predominant neuropeptide Y (NPY) receptor subtype in the brain. Y(2) receptor mRNA is discretely distributed in the brain, including specific subregions of the hippocampus and the hypothalamus, and is largely consistent with the distribution of Y(2) receptor protein demonstrated by radioligand-binding methods. Y(2) receptor-mediated effects have been reported principally based on the observations using the C-terminal fragments of NPY. Recent studies indicate an involvement of the receptor in food intake, gastrointestinal motility, cardiovascular regulation, and neuronal excitability. Very recently, Y(2) receptor selective antagonist has been developed and Y(2) receptor-deficient animals have been created. These new pharmacological tools will help to clarify the roles of this receptor in brain functions.